{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:17:27Z","timestamp":1784665047078,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Malignant cells have in contrast to non-transformed cells de-regulated transcriptional networks. The activator protein-1 (AP-1) transcription factor complex is expressed in many cancer entities including adenocarcinomas and has been correlated to de-regulated transcription and tumor-promoting mechanisms. Despite complex treatment approaches, esophageal cancer is still associated with poor overall survival. There is an urgent need for better patient stratification to increase the outcome of the multimodal treatment. This study investigated the expression of two AP-1 factors, cJUN and JUNB, and their role in 735 patients with esophageal cancer undergoing surgery. We performed immunohistochemical stainings for cJUN and JUNB and correlated the expression to the clinical outcome. Patients with a high JUNB expression level correlate to a reduced overall survival (OS) compared to patients with a low expression. Furthermore, in the multivariate analysis high JUNB expression was shown to be an independent risk factor for reduced patient survival. In addition, subgroup analysis demonstrated a significantly reduced OS for high JUNB expression in the subgroup of patients with neoadjuvant treatment. Strikingly, tumors co-expressing cJUN and JUNB were associated with poorer overall survival compared to those expressing only one or neither of the transcriptions factors. Our study suggests JUN expression as a novel biomarker to stratify patients, especially in the subgroup of neoadjuvant treated patients. Our findings have translational implications as targeting JUN might complement current available multimodal treatment approaches.<\/jats:p>","DOI":"10.1038\/s41598-025-07393-9","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:14:29Z","timestamp":1753280069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The AP-1 factor JUNB correlates with poor survival of patients with esophageal adenocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Nikolai","family":"Schleussner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Knipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Leugner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Goddemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uraz","family":"Yasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naita M.","family":"Wirsik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-On","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans F.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars M.","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane J.","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"7393_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA: A Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA: A Cancer J. Clin."},{"key":"7393_CR2","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.21037\/jtd.2017.08.72","volume":"9","author":"D Ai","year":"2017","unstructured":"Ai, D. et al. Patterns of distant organ metastases in esophageal cancer: a population-based study. J. Thorac. Dis. 9, 3023\u20133030 (2017).","journal-title":"J. Thorac. Dis."},{"key":"7393_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00419-3","volume":"18","author":"AP Thrift","year":"2021","unstructured":"Thrift, A. P. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat. Rev. Gastroenterol. Hepatol. 18, 432\u2013443 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"7393_CR4","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.3390\/cancers14246049","volume":"14","author":"KS Liu","year":"2022","unstructured":"Liu, K. S., Raza, S. A., El-Serag, H. B. & Thrift, A. P. Trends in esophageal adenocarcinoma and esophageal squamous cell carcinoma incidence in the United States from 1992 to 2019. Cancers 14, 6049 (2022).","journal-title":"Cancers"},{"key":"7393_CR5","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1245\/s10434-020-09565-5","volume":"28","author":"CT Demarest","year":"2021","unstructured":"Demarest, C. T. & Chang, A. C. The landmark series: Multimodal therapy for esophageal cancer. Ann. Surg. Oncol. 28, 3375\u20133382 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"7393_CR6","doi-asserted-by":"publisher","first-page":"eabb5647","DOI":"10.1126\/scitranslmed.abb5647","volume":"12","author":"B Dong","year":"2020","unstructured":"Dong, B. et al. Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. Sci. Transl. Med. 12, eabb5647 (2020).","journal-title":"Sci. Transl. Med."},{"key":"7393_CR7","doi-asserted-by":"publisher","first-page":"E4482","DOI":"10.1073\/pnas.1620993114","volume":"114","author":"R Jeselsohn","year":"2017","unstructured":"Jeselsohn, R. et al. Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc. Natl. Acad. Sci. 114, E4482\u2013E4491 (2017).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"7393_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.25.604999","author":"J Li","year":"2024","unstructured":"Li, J. et al. AP-1 mediates cellular adaptation and memory formation during therapy resistance. bioRxiv https:\/\/doi.org\/10.1101\/2024.07.25.604999 (2024).","journal-title":"bioRxiv"},{"key":"7393_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0955-0674(97)80068-3","volume":"9","author":"M Karin","year":"1997","unstructured":"Karin, M., Liu, Z. G. & Zandi, E. AP-1 function and regulation. Curr. Opin. Cell Biol. 9, 240\u2013246 (1997).","journal-title":"Curr. Opin. Cell Biol."},{"key":"7393_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbcan.2019.04.003","volume":"1872","author":"F Bejjani","year":"2019","unstructured":"Bejjani, F., Evanno, E., Zibara, K., Piechaczyk, M. & Jariel-Encontre, I. The AP-1 transcriptional complex: Local switch or remote command?. Biochim. Biophys. Acta (BBA) \u2013 Rev. Cancer 1872, 11\u201323 (2019).","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Rev. Cancer"},{"key":"7393_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.gt.3302158","volume":"11","author":"R Suto","year":"2004","unstructured":"Suto, R. et al. Dominant-negative mutant of c-Jun gene transfer: A novel therapeutic strategy for colorectal cancer. Gene Ther. 11, 187\u2013193 (2004).","journal-title":"Gene Ther."},{"key":"7393_CR12","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.1038\/s41598-017-05106-5","volume":"7","author":"H Xu","year":"2017","unstructured":"Xu, H. et al. Prognostic value from integrative analysis of transcription factors c-Jun and Fra-1 in oral squamous cell carcinoma: A multicenter cohort study. Sci. Rep. 7, 7522 (2017).","journal-title":"Sci. Rep."},{"key":"7393_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-024-02022-x","volume":"23","author":"T Redmer","year":"2024","unstructured":"Redmer, T. et al. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression. Mol. Cancer 23, 114 (2024).","journal-title":"Mol. Cancer"},{"key":"7393_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006879","volume":"13","author":"E Britton","year":"2017","unstructured":"Britton, E. et al. Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma. PLoS Genet. 13, e1006879 (2017).","journal-title":"PLoS Genet."},{"key":"7393_CR15","doi-asserted-by":"publisher","first-page":"001","DOI":"10.1093\/narcan\/zcad001","volume":"5","author":"S Ogden","year":"2023","unstructured":"Ogden, S. et al. Oncogenic signals through the transcription factor to control mesenchymal-like properties of oesophageal adenocarcinoma. NAR Cancer. 5, 001 (2023).","journal-title":"NAR Cancer."},{"key":"7393_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ng790","volume":"30","author":"E Passegu\u00e9","year":"2002","unstructured":"Passegu\u00e9, E., Jochum, W., Behrens, A., Ricci, R. & Wagner, E. F. JunB can substitute for Jun in mouse development and cell proliferation. Nat. Genet. 30, 158\u2013166 (2002).","journal-title":"Nat. Genet."},{"key":"7393_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc2681","volume":"10","author":"P Lopez-Bergami","year":"2010","unstructured":"Lopez-Bergami, P., Lau, E. & Ronai, Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat. Rev. Cancer 10, 65\u201376 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"7393_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/1471-2407-9-329","volume":"9","author":"S Hussain","year":"2009","unstructured":"Hussain, S. et al. Transcription factor AP-1 in esophageal squamous cell carcinoma: Alterations in activity and expression during Human Papillomavirus infection. BMC Cancer 9, 329 (2009).","journal-title":"BMC Cancer"},{"key":"7393_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bjc.6604267","volume":"98","author":"Y Shimizu","year":"2008","unstructured":"Shimizu, Y. et al. Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant. Br. J. Cancer 98, 915\u2013922 (2008).","journal-title":"Br. J. Cancer"},{"key":"7393_CR20","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s43018-021-00258-w","volume":"2","author":"M Tu","year":"2021","unstructured":"Tu, M. et al. TNF-\u03b1-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nat. Cancer 2, 1185\u20131203 (2021).","journal-title":"Nat. Cancer"},{"key":"7393_CR21","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1038\/s41467-023-41954-8","volume":"14","author":"N Schleussner","year":"2023","unstructured":"Schleussner, N. et al. Transcriptional reprogramming by mutated IRF4 in lymphoma. Nat. Commun. 14, 6947 (2023).","journal-title":"Nat. Commun."},{"key":"7393_CR22","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","volume":"21","author":"S Mathas","year":"2002","unstructured":"Mathas, S. et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 21, 4104\u20134113 (2002).","journal-title":"EMBO J."},{"key":"7393_CR23","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41375-018-0045-9","volume":"32","author":"N Schleu\u00dfner","year":"2018","unstructured":"Schleu\u00dfner, N. et al. The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17\/ILC3 skewing of anaplastic large cell lymphoma. Leukemia 32, 1994\u20132007 (2018).","journal-title":"Leukemia"},{"key":"7393_CR24","doi-asserted-by":"publisher","first-page":"e64846","DOI":"10.7554\/eLife.64846","volume":"10","author":"C Marques","year":"2021","unstructured":"Marques, C. et al. NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1. Elife 10, e64846 (2021).","journal-title":"Elife"},{"key":"7393_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/cdd.2014.157","volume":"22","author":"L Bakiri","year":"2015","unstructured":"Bakiri, L. et al. Fra-1\/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1\/2 and TGF\u03b2 expression. Cell Death Differ. 22, 336\u2013350 (2015).","journal-title":"Cell Death Differ."},{"key":"7393_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/carcin\/bgv017","volume":"36","author":"H Liu","year":"2015","unstructured":"Liu, H. et al. Aberrantly expressed Fra-1 by IL-6\/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial\u2013mesenchymal transition. Carcinogenesis 36, 459\u2013468 (2015).","journal-title":"Carcinogenesis"},{"key":"7393_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.trecan.2020.03.011","volume":"6","author":"MM Wilson","year":"2020","unstructured":"Wilson, M. M., Weinberg, R. A., Lees, J. A. & Guen, V. J. Emerging Mechanisms by which EMT Programs Control Stemness. Trends Cancer 6, 775\u2013780 (2020).","journal-title":"Trends Cancer"},{"key":"7393_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"7393_CR29","doi-asserted-by":"publisher","first-page":"e2384","DOI":"10.1038\/cddis.2016.289","volume":"7","author":"J Wu","year":"2016","unstructured":"Wu, J. et al. The Fra-1\u2013miR-134\u2013SDS22 feedback loop amplifies ERK\/JNK signaling and reduces chemosensitivity in ovarian cancer cells. Cell Death Dis. 7, e2384\u2013e2384 (2016).","journal-title":"Cell Death Dis."},{"key":"7393_CR30","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3724\/abbs.2023119","volume":"55","author":"S Li","year":"2023","unstructured":"Li, S. et al. JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis. Acta Biochim. Biophys. Sin. 55, 1784\u20131796 (2023).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"7393_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.mrrev.2011.12.003","volume":"750","author":"O Melaiu","year":"2012","unstructured":"Melaiu, O. et al. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutat. Res. Rev. Mutat. Res. 750, 132\u2013140 (2012).","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"7393_CR32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/leu.2016.358","volume":"31","author":"F Fan","year":"2017","unstructured":"Fan, F. et al. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia 31, 1570\u20131581 (2017).","journal-title":"Leukemia"},{"key":"7393_CR33","first-page":"381","volume":"147","author":"I Garajov\u00e1","year":"2008","unstructured":"Garajov\u00e1, I. et al. Gene expression profiling in prediction of tumor response to neoadjuvant concomitant chemoradiotherapy in patients with locally advanced rectal carcinoma: Pilot study. Cas. L\u00e9k. ceskych 147, 381\u2013386 (2008).","journal-title":"Cas. L\u00e9k. ceskych"},{"key":"7393_CR34","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/cas.12914","volume":"107","author":"D Kamide","year":"2016","unstructured":"Kamide, D. et al. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model. Cancer Sci. 107, 666\u2013673 (2016).","journal-title":"Cancer Sci."},{"key":"7393_CR35","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1016\/j.ymthe.2021.03.024","volume":"29","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. Mol. Ther. 29, 2583\u20132600 (2021).","journal-title":"Mol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07393-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T20:25:16Z","timestamp":1757276716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07393-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7393"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07393-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Cologne.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"26790"}}